Department of Clinical Medicine, University of Insubria, Varese, Italy.
Thromb Haemost. 2011 Oct;106(4):591-9. doi: 10.1160/TH11-02-0096. Epub 2011 Aug 25.
Some studies have suggested that high levels of total white blood cell (WBC) count and C-reactive protein (CRP) may be considered as independent prognostic factors in patients with acute coronary syndromes (ACS) and/or after cardiac revascularisation by percutaneous coronary intervention or coronary artery bypass grafting surgery. Evidence on the role of neutrophils in cardiovascular disease is less compelling. Therefore, we conducted a systematic review of the literature with the aim of identifying all the available evidence to clarify the role of neutrophils (absolute or relative count, neutrophil/lymphocyte ratio) as a prognostic risk factor in patients with ACS and/or cardiac revascularisation. All published studies evaluating the role of neutrophils as a risk factor for clinical outcomes were assessed using the MEDLINE and EMBASE databases. Study selection, data extraction and validity assessment was performed independently by two reviewers. Twenty-one studies (17 of which had positive results) for a total of more than 34,000 patients were included. Ten of 13 studies in ACS patients found that neutrophils measured on-admission are related to mortality rate and/or to major adverse clinical events. A predictive value of neutrophils after cardiac revascularisation procedures was reported in seven out of eight studies. Most of the studies showed that neutrophils were independent predictors of cardiovascular outcomes when analysed concomitantly with other markers of inflammation (WBC, CRP). The findings of our systematic review highlight the potential application of this inexpensive and readily available inflammatory marker for risk stratification in patients with ACS and/or cardiac revascularisation.
一些研究表明,总白细胞(WBC)计数和 C 反应蛋白(CRP)水平升高可被视为急性冠脉综合征(ACS)患者和/或经皮冠状动脉介入或冠状动脉旁路移植术后患者的独立预后因素。中性粒细胞在心血管疾病中的作用证据尚不充分。因此,我们对文献进行了系统评价,旨在确定所有现有证据,以阐明中性粒细胞(绝对值或相对值、中性粒细胞/淋巴细胞比值)作为 ACS 患者和/或心脏血运重建患者预后风险因素的作用。使用 MEDLINE 和 EMBASE 数据库评估了所有评估中性粒细胞作为临床结局风险因素作用的已发表研究。两位评审员独立进行了研究选择、数据提取和有效性评估。共纳入了 21 项研究(其中 17 项研究结果为阳性),总计超过 34000 例患者。在 13 项 ACS 患者研究中,有 10 项研究发现入院时测量的中性粒细胞与死亡率和/或主要不良临床事件有关。在 8 项心脏血运重建手术研究中有 7 项报告了中性粒细胞的预测价值。当与其他炎症标志物(WBC、CRP)一起分析时,大多数研究表明中性粒细胞是心血管结局的独立预测因子。我们的系统评价结果强调了这种廉价且易于获得的炎症标志物在 ACS 患者和/或心脏血运重建患者风险分层中的潜在应用。